Quarterly releaseManagement should let us know their estimate of the cost of their order to pay Novartis so we can digest and move on. Also, I really hope they don't appeal the decision...and not pursue the European lawsuit -but rather direct all attention to other priorities.
If we get some decent news in the quarterly release, including decent revenue growth and profitability, and management downplays this event and emphasizes the continued growth of their core business and the potential of their pipeline products, then we may even see the stock hold its own or even end up higher. Again, much of that depends on the results and management's comments in the release. If they stay quiet or the message is not clear, we are going down.
..